Literature DB >> 1647574

Antibody assays suitable for assessing immune responses to live varicella vaccine.

P J Provost1, D L Krah, B J Kuter, D H Morton, T L Schofield, E H Wasmuth, C J White, W J Miller, R W Ellis.   

Abstract

An enzyme-linked immunosorbent assay for antibodies to varicella-zoster virus (VZV), using purified viral glycoproteins as antigen (gpELISA), was compared with other assays for measuring vaccine-induced antibody responses. The gpELISA was more sensitive than conventional assays, proved highly specific for VZV and agreed well with an assay for neutralizing antibody activity. It was successfully applied to large-scale testing of live varicella vaccine in humans.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1647574     DOI： 10.1016/0264-410x(91)90266-9

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  21 in total

Review 1.  Successes and challenges in varicella vaccine.

Authors:  Orestis Papaloukas; Georgia Giannouli; Vassiliki Papaevangelou
Journal:  Ther Adv Vaccines       Date:  2014-03

2.  Safety and immunogenicity of Bio Pox™, a live varicella vaccine (Oka strain) in Indian children: A comparative multicentric, randomized phase II/III clinical trial.

Authors:  Anand Prakash Dubey; Mohammad Moonis Akbar Faridi; Monjori Mitra; Iqbal Rajinder Kaur; Aashima Dabas; Jaydeep Choudhury; Mallar Mukherjee; Devendra Mishra
Journal:  Hum Vaccin Immunother       Date:  2017-05-16       Impact factor: 3.452

3.  Seroepidemiologic survey of varicella-zoster virus in korean adults using glycoprotein enzyme immuno assay and fluorescent antibody to membrane antigen test.

Authors:  Yun Hwa Kim; Ji Young Hwang; Kyung Min Lee; Jin Hee Choi; Tae Yoon Lee; Jong Soo Choi; Ho Sun Park
Journal:  Ann Dermatol       Date:  2011-02-28       Impact factor: 1.444

4.  Comparative study of the standard fluorescent antibody to membrane antigen (FAMA) assay and a flow cytometry-adapted FAMA assay to assess immunity to varicella-zoster virus.

Authors:  M M Lafer; L Y Weckx; M I de Moraes-Pinto; A Garretson; S P Steinberg; A A Gershon; P S LaRussa
Journal:  Clin Vaccine Immunol       Date:  2011-05-25

5.  A double-blind, randomized, multicenter, controlled study to evaluate the immunogenicity, safety, and tolerability of varicella vaccine (VARIVAX™) passage extension 34 (PE34) process administered concomitantly with measles, mumps, and rubella vaccine (M-M-R™ II).

Authors:  Peter E Silas; Edward N Zissman; Julie Gardner; Shanjun Helian; Andrew W Lee; Heather L Platt
Journal:  Hum Vaccin Immunother       Date:  2020-05-19       Impact factor: 3.452

Review 6.  Preventing varicella-zoster disease.

Authors:  Sophie Hambleton; Anne A Gershon
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

7.  Perspectives on vaccines against varicella-zoster virus infections.

Authors:  Anne A Gershon; Michael D Gershon
Journal:  Curr Top Microbiol Immunol       Date:  2010       Impact factor: 4.291

Review 8.  Vaccination against varicella: what's the point?

Authors:  Anne A Gershon
Journal:  Adv Exp Med Biol       Date:  2010       Impact factor: 2.622

Review 9.  Microbiology laboratory and the management of mother-child varicella-zoster virus infection.

Authors:  Massimo De Paschale; Pierangelo Clerici
Journal:  World J Virol       Date:  2016-08-12

10.  A double-blind, randomized, controlled, multicenter safety and immunogenicity study of a refrigerator-stable formulation of Zostavax.

Authors:  Larry I Gilderman; James F Lawless; Thomas M Nolen; Tina Sterling; Ruth Z Rutledge; Doreen A Fernsler; Neal Azrolan; Santosh C Sutradhar; William W Wang; Ivan S F Chan; Katia Schlienger; Florian Schödel; Jeffrey L Silber
Journal:  Clin Vaccine Immunol       Date:  2007-12-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.